Dr. Edie Dullaghan is the Scientific Director of adMare Academy at adMare Bioinnovations in Vancouver, Canada.
Dr. Dullaghan obtained her PhD in the U.K. at the National Institute for Medical Research, studying the molecular genetics of the SOS response in Mycobacterium tuberculosis, the causative agent of TB. She previously served as the Pathogenomics Project Leader for Inimex Pharmaceuticals Inc. developing robust animal models of human infections with a focus toward host defense peptides and small molecules.
Throughout her career Dr. Dullaghan has managed several large programs, including leading a global collaboration with LifeArc and The Defence Science and Technology Laboratories (DSTL) in the United Kingdom using a novel approach in drug target discovery that capitalises on areas of commonality across pathogens. Currently, her focus is the scientific leadership of adMare Academy, including The BioInnovation Scientist Program which helps existing companies scale up and drive the growth of those companies into Canadian anchors by training the next generation of highly qualified personnel.